MAXCYTE, INC. Quarterly Operating Income (Loss) in USD from Q2 2020 to Q3 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Maxcyte, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2020 to Q3 2024.
- Maxcyte, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$14.1M, a 0.72% decline year-over-year.
- Maxcyte, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$46.4M, a 1.2% increase year-over-year.
- Maxcyte, Inc. annual Operating Income (Loss) for 2023 was -$48.3M, a 76.5% decline from 2022.
- Maxcyte, Inc. annual Operating Income (Loss) for 2022 was -$27.4M, a 50.4% decline from 2021.
- Maxcyte, Inc. annual Operating Income (Loss) for 2021 was -$18.2M, a 64.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)